

EXP. MAIN LABEL ER5733 20548 as 10/525783

UT15 Rec'd PCT/PTO 28 FEB 2005

AstraZeneca Docket No. 100822-1P US

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Application of: **Richard Keith**
International Application Number: **PCT/SE2003/001352**
International Filing Date: **September 1, 2003**
For: **ALPHA-7 NICOTINIC RECEPTOR AGONISTS AND STATINS IN COMBINATION**
Group Art Unit: **Not yet allocated**
Examiner: **Not yet allocated**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit herewith a list of patents and publications which they believe may be material to the patentability of claims of the above-identified application and for which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.


In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

The references listed on the attached Form PTO/SB/08a and PTO/SB/08b were cited by the Examiner in the International Search Report.

This Information Disclosure Statement is being filed within three months of the filing of the application. Accordingly, no fee is required for consideration of the references filed herewith.

Respectfully submitted,

Dated: February 28, 2005

By: 
Kenneth F. Mitchell, Ph.D.
Attorney for Applicants
Reg. No. 42,007
Telephone: 302/886-7466

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

Complete if Known 10/525783

(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	100822-1P US
-------	---	----	---	------------------------	--------------

[illegible]

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
		WO	0132620 A1	05/10/2001	AstraZeneca AB	Claims 1-12	
		WO	0042044 A1	07/20/2000	AstraZeneca AB	Claims 1-12	
		WO	9606098 A1	02/29/1996	Astra Aktiebolag	Claims 1-12	

**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(Use as many sheets as necessary)</p>				<div style="text-align: right; font-weight: bold;">Complete if Known</div> <div style="text-align: right; font-size: 1.2em;">10/525783</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>IA no. PCT/SE2003/01352</td> </tr> <tr> <td>Filing Date</td> <td>Intl. Filing Date 09/01/2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Richard KEITH</td> </tr> <tr> <td>Art Unit</td> <td></td> </tr> <tr> <td>Examiner Name</td> <td></td> </tr> <tr> <td>Attorney Docket Number</td> <td>100822-1P US</td> </tr> </table>		Application Number	IA no. PCT/SE2003/01352	Filing Date	Intl. Filing Date 09/01/2003	First Named Inventor	Richard KEITH	Art Unit		Examiner Name		Attorney Docket Number	100822-1P US
Application Number	IA no. PCT/SE2003/01352																
Filing Date	Intl. Filing Date 09/01/2003																
First Named Inventor	Richard KEITH																
Art Unit																	
Examiner Name																	
Attorney Docket Number	100822-1P US																
Sheet	1	of	1														

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		H. JICK ET AL, "Statins and the risk of dementia," Lancet, p. 1627-1631, (November 11, 2000).	
		JOSEPH D. BUXBAUM ET AL., "Pharmacological concentrations of the HMG-COA reductase inhibitor lovastatin decrease the formation of the alzheimer Beta-amyloid peptide in vitro and in patients.," Frontiers in Bioscience, p. 50-59, (April 1, 2002).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.